← Kyowa Kirin Pharmaceutical Development (KYKOY) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Kyowa Kirin Pharmaceutical Development (KYKOY)
Healthcare · market cap $7.8B · as of 2026-07-11
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-15 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Kyowa Kirin Pharmaceutical Development (KYKOY) is a healthcare-sector company with approximately 5,669 employees and a market cap of ~$8.15B, operating a broad pipeline spanning rare bone diseases, hematologic malignancies, neurology, and pain. Its lead asset is an Oral Phosphate Supplement in Phase 3 for X-Linked Hypophosphatemia (XLH), alongside burosumab (KRN23 analog) also in Phase 3 for XLH and related rare bone conditions. The nearest near-term catalyst is a Phase 2 readout for KHK4951 estimated around August 31, 2026.
The catalyst path
- 2026-11-15 (est.)Phase 2 · DA-EPOCH Protocolimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| KW-6002 (istradefylline) | Phase 2 | Parkinson's Disease |
| Mogamulizumab | Phase 2 | Cutaneous T-Cell Lymphoma, Relapsed |
| Oral Phosphate Supplement | Phase 3 | X-Linked Hypophosphatemia |
| Burosumab | Phase 3 | X-linked Hypophosphatemia (XLH) |
| KW-3357 | Phase 3 | Disseminated Intravascular Coagulation (DIC) |
| darbepoetin alfa | Phase 3 | Anemia |
| KHK7791 | Phase 3 | Hyperphosphatemia |
| KW-0761 | Phase 3 | Adult T-cell Leukemia-lymphoma |
| ARQ 197 | Phase 2 | Non-small-cell Lung Cancer |
| EN3267 | Phase 3 | Pain |
| KHK4083 | Phase 2 | Atopic Dermatitis |
| KRN23 | Phase 3 | Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome |
| KW-2246 (fentanyl citrate) | Phase 3 | Pain, Cancer |
| Romiplostim | Phase 3 | Aplastic Anemia |
| KW-6356 | Phase 2 | Parkinson's Disease |
| Pegfilgrastim | Phase 2 | Peripheral Blood Stem Cell Transplantation |
| OPC-262 | Phase 3 | Diabetes, Type 2 |
| KHK7580 | Phase 3 | Parathyroid Carcinoma |
| Vorinostat | Phase 3 | Cutaneous T-Cell Lymphoma |
| Istradefylline (KW-6002) | Phase 3 | Parkinson's Disease |
Price & technical context
3-month
-13.5%
6-month
-12.8%
12-month
-11.7%
52-wk range
$13.69–$18.66
vs 50-day MA
-11.0%
vs 200-day MA
-11.4%
Realized vol
47.9%
Max drawdown
-33.0%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for KYKOY (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.